Voluntary Medical Male Circumcision Clinical Trial
— 2WTOfficial title:
Reducing Provider Workload While Preserving Patient Safety: A 2-Way Texting Intervention in Zimbabwe's Voluntary Medical Male Circumcision Program
Verified date | March 2020 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Voluntary medical male circumcision (VMMC) in sub-Saharan Africa is safe: the average rate of moderate and severe adverse events (AEs) at the country level is 0.8%, corresponding to 99% of men healing without incident. To reach the global target of 20 million by 2018, VMMC productivity needs to double in countries already plagued by severe healthcare worker shortages like Zimbabwe. The ZAZIC consortium partners with the Zimbabwe Ministry of Health and Child Care (MoHCC) and performed over 120,000 VMMCs. Current VMMC care in Zimbabwe requires in-person, follow-up visits at post-operative days 2,7, and 42. Over 95% adhere to multiple follow-up visits within 14 days of VMMC. ZAZIC's program has an overall AE rate of 0.4%; therefore, overstretched clinic staff conducted more than 200,000 unnecessary reviews for VMMC clients without complications. High mobile phone ownership, severe healthcare worker shortages, and rapid VMMC scale up make ZAZIC's VMMC program an ideal setting to test a mobile health (mHealth) intervention to reduce provider workload while safeguarding patient safety. Through an un-blinded, prospective, randomized, control trial (RCT) in high-volume facilities providing VMMC, ZAZIC will implement an interactive, two-way texting (2wT) intervention to identify men healing without complication, allowing them to decline routine in-person follow up visits. 2wT will simultaneously identify men with any sign of an adverse event, encouraging rapid in-person follow-up when an AE is suspected on any day, reducing unnecessary visits while maintaining quality care. We aim to 1) determine if 2wT can safely reduce VMMC follow-up visits; 2) estimate the cost savings associated with 2wT over routine VMMC follow-up; and 3) assess the acceptability and feasibility of 2wT for further scale-up. It is expected that this intervention with be as safe as routine care while providing distinct advantages in terms of efficiency, costs, and reduced healthcare worker burden. This approach is innovative as it focuses on using a low-cost mHealth intervention to reduce provider workload without deterioration in quality care. The success of this intervention could lead to adoption of this intervention at the national level, increasing efficiency of VMMC scale up and reducing burdens on providers and patients
Status | Completed |
Enrollment | 780 |
Est. completion date | August 30, 2019 |
Est. primary completion date | February 28, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion: For health care workers (Aim 3): 1. are employees posted at the site; 2. are at least 18 years of age or over; 3. provide health care services to patients as part of the VMMC programs; and 4. are able to provide written informed consent. For VMMC clients (Aims 1): Eligibility criteria for VMMC clients are: 1. 18 years or older; 2. possession of own phone at enrollment; 3. provides contact details (phone, physical location); 4. receives surgical VMMC; 5. willing to follow MoHCC VMMC protocols; 6. willing to come in Day 14; 7. Able and willing to respond to a questionnaire administered by phone 42 days after circumcision. Exclusion for Healthcare workers: 1. not willing to participate 2. not willing to be recorded Exclusion for VMMC clients: 1. men without cell phones; 2. those who chose PrePex as PrePex requires a device-removal visit 7 days after placement and has distinctly different follow-up protocols; 3. men who have an inter-operative AE during routine VMMC will be withdrawn from the study as these men will have known, additional follow-up risks and mandatory in-person visits. |
Country | Name | City | State |
---|---|---|---|
Zimbabwe | 1. Chitungwiza Central Hospital | Chitungwiza | Stand Number 12096 Batanai ROAD Zengeza 4 |
Zimbabwe | 2. South Medical Citimed Chitungwiza Hospital | Chitungwiza | Stand Number 14656 Zengeza 4 |
Zimbabwe | Zengeza 3 Clinic | Chitungwiza | Stand Number: 7723 Cheuka WAY Zengeza 3 |
Zimbabwe | 5. Seke North Clinic | Seke North | Stand Number: 16106 UNIT G |
Zimbabwe | 4. Seke South Clinic | Seke South | Stand Number: 19188 UNIT L |
Lead Sponsor | Collaborator |
---|---|
University of Washington | International Training and Education Center for Health, Medic Mobile, University of Zimbabwe, ZICHIRe |
Zimbabwe,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cumulative adverse event (AE) rate (moderate or severe) | Incidence of AEs before Day 14 will be extracted from routine VMMC data for both 2wT and control. Incident AEs on Day 14 will be identified, classified, and graded for severity using routine MoHCC protocols [26] and recorded on routine VMMC AE forms. The investigators will compare cumulative rates of any moderate or severe AE = Day 14 between groups using Fisher's exact test as the expected number of AEs is low. The rates will be calculated per arm as: (# moderate + severe AEs)/(total # VMMC clients who attend 2, 7 or 14 Day follow-up visit). Multivariate logistic regression models (any AE v none) will quantify the magnitude of difference, adjusting for any potential confounders. | = Day 14 for each participant with analysis completed in year 1. | |
Primary | Mean number of in-person visits | To determine follow-up visit reduction, the investigators will compare the mean number of in-person visits for intervention and control using a t-test. A multivariate linear regression model will further quantify the effect of intervention on visit reduction, adjusting for potential confounders. | Before 42 day visit for each participant with analysis completed in year 1. | |
Primary | 2wT costs | The investigators will calculate the relative costs and outcomes (effects) of intervention versus control, including costs for technology, healthcare worker time, and client considerations (travel, text costs, missed work). The investigators will conduct both activity-based costing from the implementation perspective and from the technology perspective to extrapolate results as costs that would be incurred by the MoHCC should they elect widespread scale up of 2wT. | The costing data collection will be completed by April 2018 at the completion of all study participant follow-up. Analysis will conclude in year 1 | |
Primary | 2WT acceptability | 2wT acceptability, using study recruitment and enrollment logs in addition to the texting database, the investigators will describe levels of acceptance, participation, refusal and drop-out. The investigators will carry out key informant interviews (KIIs) with up to 8 health care workers to gauge acceptability, satisfaction, identify facilitators and barriers to program success, and ascertain suggestions for intervention improvement. KIIs will be audio recorded and transcribed. The investigators will also implement questionnaires at the Day 14 visit with a subset of 100 2wT VMMC clients to gauge satisfaction, estimate direct and indirect costs (time away from work, transportation costs), and ascertain suggestions for intervention improvement. | The acceptability activities will be completed by April 2018 at the completion of all study participant follow-up with analysis to commence after that point. Analysis will conclude in year 1. | |
Primary | 2WT feasibility | For feasibility, costing data will be combined with usability and acceptability information. | The feasibility activities be completed by April 2018 at the completion of all study participant follow-up with analysis to commence after that point. Analysis will conclude in year 1. | |
Secondary | AE rates on Day 14 | AE rates on Day 14 | Day 14 data collection for each participant with analysis to be completed in year 1. | |
Secondary | severity of AEs. | severity of AEs. | Day 14 data collection for each participant with analysis to be completed in year 1. | |
Secondary | time between 2wT AE text reporting and follow-up | time between 2wT AE text reporting and follow-up | Day 14 data collection for each participant with analysis to be completed in year 1. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06364891 -
Assessing the Impact of a Digital VMMC Platform
|
N/A | |
Completed |
NCT04327271 -
Two-way Texting for VMMC Follow-up in Republic of South Africa
|
N/A | |
Completed |
NCT01857700 -
Economic Compensation to Increase Demand for Voluntary Medical Male Circumcision
|
N/A |